The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...

The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based ...

The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) to treat unresectable or ...

First approval in the US for AstraZeneca and Daiichi Sankyo’s DATROWAY based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death vs. chemotherapy ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

The first patient has been dosed in the TROPION-Lung12 phase 3 trial evaluating the efficacy and safety of adjuvant Datroway (datopotamab deruxtecan) plus rilvegostomig or rilvegostomig monotherapy ...

The green light from the European Medicines Agency is the first backing in the EU for the medicine, following its approval in ...

The European Medicines Agency has recommended three new medicines to treat breast and cervical cancer and ...

First approval in the U.S. for Daiichi Sankyo and AstraZeneca’s DATROWAY based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death versus chemotherapy ...

WILMINGTON, Del., January 17, 2025--(BUSINESS WIRE)--DATROWAY ® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic ...